Weight-Loss Drugs Transform Fashion Shopping Habits

Published: 11 July 2026.The English Chronicle Desk. The English Chronicle Online.
The rapid rise of GLP-1 weight-loss medications is reshaping consumer behaviour far beyond the healthcare sector, with fashion retailers emerging among the biggest beneficiaries. As millions of people in the UK and the United States lose significant amounts of weight through medicines such as Wegovy, Mounjaro and new oral weight-loss pills, they are also transforming the way they shop, dress and spend their money.

Retail analysts say the phenomenon is creating an entirely new category of consumers whose priorities are shifting from food and alcohol towards clothing, fitness, skincare and personal wellbeing. The trend is already influencing fashion sales, changing sizing patterns and forcing retailers to rethink product ranges, while presenting fresh challenges for businesses serving the plus-size market.

For many people, the physical transformation brought about by GLP-1 medicines has also become an emotional and psychological journey, restoring confidence and allowing them to embrace styles they once avoided.

Hayley Grice, a 50-year-old business owner from Shropshire, represents one of the growing number of people whose shopping habits have dramatically changed after using Mounjaro. Having lost seven dress sizes over the past two years, she says clothes shopping has transformed from a frustrating necessity into an enjoyable experience.

For most of her adult life, Grice wore UK sizes 26 to 28 and found herself limited to specialist plus-size retailers. Fashion choices were often dictated by availability rather than personal taste, leaving little room for experimentation or self-expression.

Now wearing a UK size 12, she shops in mainstream high street stores and says she no longer avoids bright colours or eye-catching outfits. Instead of choosing clothing designed to blend into the background, she now selects garments simply because she enjoys wearing them, reflecting a renewed sense of confidence.

Her experience mirrors a much broader trend identified by market researchers across Britain and North America.

According to consultancy PwC, around five percent of UK adults—almost three million people—are currently using GLP-1 medications, while approximately nine percent have tried them at some point. The consultancy forecasts that figure could reach thirteen percent by the end of next year, meaning around seven million Britons may have experience with the treatments.

PwC believes these medicines are creating a new type of consumer whose purchasing decisions increasingly prioritise health, wellbeing and appearance.

The research shows that around sixty percent of current GLP-1 users are women. Usage is particularly common among adults aged between twenty-five and forty-four, with women aged thirty-five to fifty-four also representing a significant proportion of users. Analysts note that wealthier households currently account for a higher percentage of users, although wider availability and lower prices may broaden access in the years ahead.

The arrival of oral GLP-1 medicines is expected to accelerate that trend.

This week marked the launch of oral Wegovy in the UK through private prescription, making it the first tablet version of the popular weight-loss medicine available to British patients. The once-daily pill follows its successful introduction in the United States earlier this year, where demand has exceeded expectations.

Pharmacies across Britain are preparing for increased enquiries as patients who previously disliked injections consider tablet alternatives. Eli Lilly has also introduced its competing oral medicine, Foundayo, known scientifically as orforglipron, further expanding treatment options.

Private prices for oral Wegovy currently range from approximately £69 per month for introductory doses to around £269 for higher strengths. Injectable versions remain available at comparable prices, while Mounjaro pricing varies depending on dosage.

Medical professionals continue to stress that GLP-1 medicines should only be taken under appropriate clinical supervision. While highly effective for many patients, the drugs may cause side effects including nausea, vomiting, constipation and diarrhoea. In some cases, more serious complications such as kidney problems have also been reported.

Despite those risks, consumer behaviour is changing rapidly.

Research from PwC, Mintel and Circana consistently shows that users tend to purchase healthier foods, reduce alcohol consumption and spend more on clothing, cosmetics, sports equipment and health-monitoring technology.

Fashion appears to be one of the sectors experiencing the greatest impact.

In Britain, more than four in ten GLP-1 users report spending more on clothes after losing weight. Many are investing in activewear as they become more physically active, while others are buying occasion wear for social events they previously felt uncomfortable attending.

Retail experts describe the emergence of a “transition wardrobe” as customers replace clothing multiple times while progressing through different sizes during their weight-loss journey.

American consumer Melody Ewert has experienced similar changes after nearly a year using GLP-1 treatments. Although she briefly switched to oral Wegovy before returning to injectable medication due to side effects, she says shrinking clothing sizes have required regular wardrobe updates.

Rather than purchasing expensive designer clothing immediately, she currently relies on second-hand shops and discounted items while continuing towards her weight-loss goal. She notes that undergarments require replacement more frequently than outerwear, while her clothing choices have become brighter and more colourful as her confidence grows.

Researchers suggest these behavioural changes are becoming increasingly visible throughout the fashion industry.

Medical studies have shown that Wegovy users lost an average of around twenty-one kilograms over seventy-two weeks during clinical trials, equivalent to approximately four dress sizes. Even more modest weight reductions often require consumers to replace substantial portions of their wardrobes.

Stephen Fitzgerald, former commercial director at Marks & Spencer, believes even a five-kilogram reduction can translate into a full clothing size change. With forecasts suggesting up to fifteen percent of the UK population could eventually use GLP-1 medicines, retailers are preparing for sustained demand.

Investment bank Berenberg estimates that weight-loss medicines could boost Britain’s clothing market by approximately one percent annually over each of the next three years.

Mid-market retailers such as Marks & Spencer, Next and Zara are expected to benefit most because their customer base overlaps with the demographic currently adopting GLP-1 treatments.

Marks & Spencer has already reported changing purchasing patterns. In several womenswear categories, including jeans, smaller sizes between UK 6 and 12 now account for around sixty-five percent of sales, compared with roughly forty percent historically.

Meanwhile, the picture is proving much more difficult for specialist plus-size retailers.

Businesses serving larger customers report falling sales as more consumers move into standard sizing. London-based retailer BeigePlus says sales have declined by around twenty percent over the past two years, describing the commercial impact as severe despite welcoming the health improvements experienced by many customers.

Industry leaders also warn that the shrinking plus-size market could reduce the availability of inclusive fashion, leaving customers who continue to require extended sizing with fewer options.

The beauty industry is also adapting to changing consumer needs.

Rapid weight loss can sometimes leave loose skin or changes in facial appearance commonly referred to as “Ozempic face.” In response, skincare and haircare brands have introduced products specifically marketed towards GLP-1 users seeking to maintain skin elasticity and minimise hair thinning.

Fashion analysts believe the wider shift in consumer behaviour may even be influencing design trends. Following years dominated by oversized, relaxed silhouettes during and after the COVID-19 pandemic, retailers are increasingly introducing more structured, tailored and body-conscious styles that reflect changing customer preferences.

For millions of consumers, however, the biggest transformation extends beyond wardrobes or shopping habits. The ability to choose clothes based on personal style rather than physical limitations represents a powerful emotional milestone.

As GLP-1 medicines continue gaining popularity worldwide, their influence is expected to stretch far beyond healthcare, reshaping retail, fashion and consumer spending patterns for years to come.